Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Fineline Cube Feb 25, 2026
Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Fineline Cube Feb 25, 2026
Company Deals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Fineline Cube Feb 25, 2026
Company Deals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Fineline Cube Feb 25, 2026
Company Deals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

Fineline Cube Feb 25, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label

Fineline Cube Feb 25, 2026
Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Fineline Cube Feb 25, 2026
Company Deals

MSD Partners with Variational AI to Harness Generative AI for Drug Discovery

Fineline Cube Jan 26, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian...

Company Drug

Gan & Lee Pharmaceuticals Receives Bolivian Approval for Insulin Aspart, Expanding Access to Rapid-Acting Insulin

Fineline Cube Jan 26, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...

Policy / Regulatory

China’s NHC Designates 100 Areas as National Demonstration Zones for Integrated Medical and Elderly Care

Fineline Cube Jan 26, 2024

The National Health Commission (NHC) has announced the selection of 100 counties (cities, districts), including...

Company Drug

Roche Commences Phase II Trial of Repare Therapeutics’ ATR Inhibitor, Camonsertib, in Solid Tumors

Fineline Cube Jan 26, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has reached a significant milestone this week with the...

Company Drug

Roche’s Tecentriq in Combination with Exelixis’s Cabometyx Meets Primary Endpoint in mCRPC Phase III Study

Fineline Cube Jan 26, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced positive results from a Phase III...

Company Drug

Pfizer’s Nurtec Approved by China’s NMPA for Acute Treatment of Migraines

Fineline Cube Jan 26, 2024

Pfizer Inc. (NYSE: PFE), a leading pharmaceutical company in the U.S., has announced that it...

Company Drug

Novo Nordisk’s Rybelsus Approved for Type 2 Diabetes in China, Setting New Oral Treatment Standard

Fineline Cube Jan 26, 2024

Novo Nordisk (NYSE: NVO), a major Danish pharmaceutical company, has received approval from China’s National...

Company

BJ Bioscience Inc. Faces Bankruptcy as Hangzhou Court Accepts Liquidation Application

Fineline Cube Jan 25, 2024

The Hangzhou Yuhang District People’s Court has released a document indicating that BJ Bioscience Inc.’s...

Company

Wantai Biological Forecasts Sharp Drop in 2023 Net Profits Amid HPV Vaccine Sales Slump

Fineline Cube Jan 25, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, has issued...

Company Drug

Eli Lilly’s Subsidiary Akouos Reports Positive Preliminary Results for Gene Therapy in Hearing Loss

Fineline Cube Jan 25, 2024

Eli Lilly (NYSE: LLY) has announced preliminary results from a Phase I/II study conducted by...

Company Deals R&D

Shanghai Pharmaceuticals and HKSTPC Launch 01LABS@Hong Kong Incubator

Fineline Cube Jan 25, 2024

01LABS@Hong Kong, a Shanghai-Hong Kong innovation incubator, has officially commenced operations. The incubator was jointly...

Company Drug

Biosion’s SIRPα-Targeting Monoclonal Antibody BSI-082 Clears US FDA Clinical Trial Hurdle

Fineline Cube Jan 25, 2024

Biosion, a global clinical-stage biotechnology company dedicated to developing antibody-based therapies for immune and oncologic...

Company Drug

IASO Biotherapeutics Secures NMPA Approval for Fucaso in Refractory Myasthenia Gravis

Fineline Cube Jan 25, 2024

China-based IASO Biotherapeutics has received clinical trial approval from the National Medical Products Administration (NMPA)...

Company Drug

MSD’s Keytruda Combines with PharmAbcine’s PMC-309 in Phase Ia/b Solid Tumor Trial

Fineline Cube Jan 25, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its blockbuster anti-PD-1 drug Keytruda...

Policy / Regulatory

NMPA Proposes Streamlined Market Approval Process for Domestically Produced Overseas Drugs

Fineline Cube Jan 25, 2024

The National Medical Products Administration (NMPA) has released a draft proposal titled “Optimizing the Market...

Company Deals

GSK In-Licenses Elegen’s Cell-Free DNA Tech to Advance Next-Gen Gene Therapies and Vaccines

Fineline Cube Jan 25, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has this week in-licensed US partner Elegen’s...

Policy / Regulatory

NMPA Expands Generic Drug Catalog with 74th and 75th Batches for Quality Consistency Evaluation

Fineline Cube Jan 25, 2024

The National Medical Products Administration (NMPA) has released the 74th and 75th batches of reference...

Company Drug

China Grand Pharmaceutical Gets NMPA Green Light for mRNA Cancer Vaccine ARC01 Phase I Study

Fineline Cube Jan 25, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has...

Company Deals Hospital

China Anti-Cancer Association Forms Consortium for Standardizing Cancer Research Ethics Reviews

Fineline Cube Jan 25, 2024

The medical ethics professional committee of the China Anti-Cancer Association (CACA) has announced the formation...

Company Drug

Boan Biotech Secures FDA Orphan Drug Designations for Two Claudin18.2 Targeting Candidates

Fineline Cube Jan 25, 2024

Boan Biotech (HKG: 6955), a Chinese biotechnology company, has announced that it has received orphan...

Posts pagination

1 … 369 370 371 … 626

Recent updates

  • Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label
  • United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential
  • Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer
  • Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD
  • MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label

Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Company Drug

Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.